HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
ORGO
Organogenesis Holdings Inc.
ORGO lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
ORGO Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Under pressure | |
| Strong |
ORGO's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
ORGO PE Valuation
ORGO has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
ORGO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong decline | |
| Strongly weakening | |
| Limited | |
| Moderate |
Analysts expect ORGO's losses to shrink, with revenue declining.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has the edge over ORGO on earnings, with more consistent year-over-year improvement.
ORGO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.15 | -$1.04 |
| Q2 2026 | -$0.79 | -$0.66 |
| Q1 2026 | -$0.12 | +$0.04 |
| Q4 2025 | $0.15 | +$0.16 |
| Q3 2025 | -$0.11 | -$0.05 |
| Q2 2025 | -$0.13 | $0.00 |
| Q1 2025 | -$0.16 | -500% |
| Q4 2024 | -$0.01 | -125% |
ORGO lost $1.15 per share over the past year, and its loss has widened in each of the last three quarters.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over ORGO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over ORGO on profitability, with a higher operating margin.
ORGO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $45.5M | -70% |
| Q2 2026 | $43.8M | -57% |
| Q1 2026 | $37.2M | -57% |
| Q4 2025 | $225.6M | +78% |
| Q3 2025 | $150.9M | +31% |
| Q2 2025 | $101M | -22% |
| Q1 2025 | $86.7M | -21% |
| Q4 2024 | $126.7M | +27% |
ORGO's revenue is shrinking: $45M last quarter, down 70% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -65% | -79 points |
| Q2 2026 | -117% | -104 points |
| Q1 2026 | -185% | -154 points |
| Q4 2025 | 28% | +20 points |
| Q3 2025 | 14% | +8.3 points |
| Q2 2025 | -12% | -1.8 points |
| Q1 2025 | -31% | -27 points |
| Q4 2024 | 8.1% | +9.3 points |
ORGO's operating margin was −65% last quarter, down 79 points from the same quarter a year ago, near the bottom of its range since 2019.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over ORGO on cash generation, producing positive trailing cash flow while its opponent burns cash.
ORGO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$20.1M | -2477% |
| Q2 2026 | -$32.8M | +$3.8M |
| Q1 2026 | $18M | +$41.5M |
| Q4 2025 | $34.8M | +359% |
| Q3 2025 | $844K | -86% |
| Q2 2025 | -$36.5M | -1378% |
| Q1 2025 | -$23.6M | -$11.2M |
| Q4 2024 | $7.6M | +3.9% |
ORGO's free cash flow was −$64,000 over the past year, against −$52M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over ORGO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
ORGO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +316K shares |
| 1 year | -1.4% | -1.9M shares |
| 3 years | -3.3% | -4.4M shares |
| 5 years | -3.6% | -4.9M shares |
| Available history | +39% | +36.2M shares |
ORGO has 129M diluted shares, down 1.4% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has the edge over ORGO on leverage, with a lower net debt burden relative to earnings.
ORGO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -4.9x | Net Cash |
| Q4 2025 | -1.6x | Net Cash |
| Q3 2025 | -9.9x | Net Cash |
| Q4 2024 | -10.2x | Net Cash |
| Q3 2024 | -13.6x | Net Cash |
| Q2 2024 | -6.0x | Net Cash |
| Q1 2024 | -0.8x | Net Cash |
| Q4 2023 | -1.3x | Net Cash |
ORGO has more cash than debt.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
ORGO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 27.3 | Oversold |
| Stochastic | 7.8 | Oversold |
ORGO's weekly RSI is 27 (oversold) and its Stochastic is 8 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
ORGO PE vs Healthcare Sector
| Metric | ORGO | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
ORGO has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
ORGO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.07 | 10% below |
| 20 week MA | $1.63 | 41% below |
| 50 week MA | $2.60 | 63% below |
| 100 week MA | $3.40 | 72% below |
| 200 week MA | $3.18 | 70% below |
ORGO is in a downtrend: it's below all five of its weekly moving averages, and 70% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over ORGO on returns for 2026, with the stronger performance.
ORGO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $4.94 | $6.46 | +31% |
| 2021 | $6.46 | $10.2 | +58% |
| 2022 | $10.2 | $2.59 | -75% |
| 2023 | $2.59 | $4.09 | +58% |
| 2024 | $4.09 | $3.19 | -22% |
| 2025 | $3.19 | $5.28 | +66% |
| 2026 YTD | $5.28 | $0.96 | -82% |
ORGO is down 82% so far in 2026, after finishing higher in four of the previous six years.